pulmonary embolism

Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？

By MedXY 08/26/2025

An 18-month course of rivaroxaban significantly lowers recurrent venous thromboembolism compared to 6 months in cancer patients with low-risk pulmonary embolism without a substantial increase in major bleeding risk.

Medical News Wellness & Lifestyle

Global Shifts in Pulmonary Embolism Mortality: A 2001-2023 WHO Database Analysis

By MedXY 08/25/2025

Analysis of WHO data reveals declining global pulmonary embolism mortality overall, with marked differences by region and income, highlighting urgent needs in lower-middle-income countries.

Clinical Updates Wellness & Lifestyle

Elevated D-Dimer Levels: Beyond Pulmonary Embolism—Uncommon Conditions Many Doctors Overlook

By MedXY 08/03/2025

D-dimer is a specific fibrin degradation product indicative of blood clot formation and breakdown. Elevated levels signal various conditions beyond pulmonary embolism, including cardiovascular diseases, malignancies, and infections.